

Myelopro Diagnostics and Research GmbH obtains an exclusive worldwide license from CeMM to develop therapeutics, targeting mutated calreticulin protein in malignant diseases

CALR mutations have been discovered by the research team of Robert Kralovics at CeMM as highly disease-specific markers to a blood cancer called myeloproliferative neoplasms (MPN). Recently, the relevance of CALR mutations have been recognized by the WHO, including them as one of the major diagnostic criteria.

As a unique, disease-specific peptide, mutated CALR is also an attractive target to develop therapies. "This licensing agreement enables Myelopro to continue research on the therapeutic exploitation of mutated CALR in a disease area with an unmet medical need. We are making excellent progress and are very excited to partner with CeMM, a world-class research institution," states Oleh Zagrijtschuk, CEO of Myelopro. The above mentioned license agreement excludes diagnostic use of the CALR mutation.

The biotech company QIAGEN exclusively licensed the technology from CeMM in 2014 in order to develop a diagnostic test for the CALR mutations offering each patient a clearer prognostic profile and guiding disease management.

The mission of CeMM is to achieve maximum innovation in precise and personalized molecular medicine to improve healthcare. A committed team of scientists and medical doctors pursue free basic research in the life sciences fully engrafted in a large and vibrant hospital environment of great medical tradition and practice. Partnerships with biotech or pharma companies facilitate following up on research results by providing solutions to medical doctors and patients.

References

1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagiński K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. 2013 Dec 19;369(25):2379-90.
2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016 May 19;127(20):2391-405.

About Myelopro

Myelopro Diagnostics and Research GmbH is a start-up biopharmaceutical company, developing drugs and offering drug development services. The company is headquartered in Vienna, Austria. Contact: Myelopro Diagnostics and Research GmbH, Lazarettgasse 14, AKH BT 25.3, 1090 Vienna, Austria, office@myelopro.com

About CeMM

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is an interdisciplinary research institute committed to advancing the understanding of human diseases through basic and biomedical research. Located at the center of the Medical University of Vienna's campus, CeMM fosters a highly collaborative and interactive research mindset. Focusing on medically relevant questions, CeMM researchers concentrate on human biology and diseases like cancer and inflammation/immune disorders. In support of scientific pursuits and medical needs, CeMM provides access to cutting-edge technologies and has established a strategic interest in personalized medicine. Since 2005, Giulio Superti-Furga is the Scientific Director of CeMM.

www.cemm.at

For further information please contact

Mag. Wolfgang Däuble

Media Relations Manager

CeMM

Research Center for Molecular Medicine
of the Austrian Academy of Sciences
Lazarettgasse 14, AKH BT 25.3
1090 Vienna, Austria
Phone +43-1/40160-70 057
Fax +43-1/40160-970 000
wdaeuble@cemm.oeaw.ac.at
www.cemm.at

